RT Journal Article
SR Electronic
T1 High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5631
OP 5639
DO 10.21873/anticanres.14576
VO 40
IS 10
A1 YUKI MINAGAWA
A1 KOUSUKE ISHINO
A1 RYUICHI WADA
A1 MITSUHIRO KUDO
A1 ZENYA NAITO
A1 TOSHIYUKI TAKESHITA
A1 RYUJI OHASHI
YR 2020
UL http://ar.iiarjournals.org/content/40/10/5631.abstract
AB Background/Aim: DNA damage response (DDR), wherein p21 is a cell fate determinant, is a potential cancer therapeutic target. Molecular expression during DDR was explored in ovarian clear-cell carcinoma (CCC). Materials and Methods: CHK1, CHK2, TP53 and p21 expression in DDR was examined using immunostaining in surgical sections of CCC (n=22). Molecular alterations in two types of CCC cell lines, JHOC-5 and JHOC-9, were investigated using western blot analysis. Results: Expression of DDR-associated molecules was noted in most patients. While high p21 expression was found in half of the patients, the remaining patients exhibited low p21 expression. Treatment with UC2288, a p21 inhibitor, attenuated proliferation of both cell lines, more prominently in JHOC-9, resulting in reduced viability and subsequent apoptosis. Conclusion: p21 Inhibitor induced cell death in cells with high p21 expression, suggesting that p21 suppression can be a therapeutic strategy to treat patients with CCC.